Center on Health Equity & Access

At AMCP 2026, Kelsea Aragon, PharmD, discussed PrEP coverage, long-acting injectables, and payer strategies to improve HIV treatment access and adherence.

Quality metrics for screening tests must evolve to mandate diagnostic resolution, ensuring financial and clinical incentives prioritize the complete screening continuum over initial test uptake.

At AMCP 2026, Adam Colborn, JD, warns the Alternatives to PAIN Act may expand access but risk destabilizing Medicare Part D and limiting plan participation.

Abby Kim, PharmD, delves into oncology trends, biomarker testing gaps, and evolving clinical pathways shaping precision care and treatment decisions.

The 2026 Regional Diabetes Summit is taking place from April 28 to 29, 2026, in Wilmington, Delaware.

Ben Urick, PharmD, PhD, examines GLP-1 coverage gaps and real-world evidence challenges shaping payer decisions and obesity treatment access.

Hayley Knollman, MD, explains how ctDNA and genomic testing impact ER-positive metastatic breast cancer care, guiding sequencing decisions amid evolving HER2 categories.

High co-payments for potentially curative cell and gene therapies create avoidable access barriers; value-based insurance design should eliminate patient cost sharing for these therapies.

At AMCP 2026, Daryl Pritchard, PhD, highlighted fragmentation, evidence gaps, and decision support needs limiting precision medicine adoption and outcomes.

Kelsea Aragon, PharmD, highlights the role of long-acting HIV therapies like lenacapavir and cabotegravir in improving adherence, flexibility, and prevention access.

Steven Kheloussi, PharmD, explains how care coordination and transparent policies can improve MS treatment adherence, streamline access, and balance costs.

Complex Medicaid patients randomly assigned to receive outpatient social worker care coordination services experienced increased hospitalizations but no differences in emergency department visits or costs.

Esketamine's monotherapy approval and new real-world data are forcing a reckoning for managed care.

A clinical pharmacy leader outlines 8 interdependent domains institutions must master to build financially sustainable, patient-accessible CGT programs.

Amy Leader, DrPH, MPH, explains that trust is key to clinical trial enrollment at an Institute for Value-Based Medicine event in Philadelphia.

The global prevalence of MASLD was 16.1% as recently as 2023, with many individuals being asymptomatic and carrying a major risk of future complications.

Equity gaps in lung cancer molecular testing persist; reflex testing and nurse navigation speed care, while coverage and access barriers stall outcomes

Housing and transportation barriers were linked to lower CRC screening rates, especially among adults aged 50 to 64.

Reflex molecular testing and nurse navigation cut delays in lung cancer care, helping more patients get targeted results before first-line therapy, says Christopher D'Avella, MD.

Why Medicaid-covered kids struggle to see pediatricians: low reimbursement and practice deserts in low-income ZIP codes create real barriers to care.

Nancy L. Lewis, MD, MBS, FACP, discusses her path from the clinic to biopharma and her goals as NCCN's new CSO, including health equity and faster drug development.

Two AAD 2026 posters highlight persistent melanoma disparities: men have worse survival, whereas minority patients are less likely to receive home or hospice end-of-life care.

Study finds rural Appalachia faces soaring insomnia and sleep apnea, tied to poverty and stress, urging targeted, equity-focused sleep interventions.

Major health plans cut millions of preapproval hurdles, add 90-day continuity protections, and push real-time e-authorization to speed care access.

Despite a 24% drop since 2015, over 4 million Americans remain on long-term opioids, and they’re older, on Medicare, and increasingly coprescribed risky drugs.